Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Trial Profile

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2016

At a glance

  • Drugs Bendamustine (Primary) ; Rituximab
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Pharmatec
  • Most Recent Events

    • 09 May 2012 Actual patient number (61) added as reported by ClinicalTrials.gov.
    • 09 May 2012 Planned End Date changed from 1 Nov 2010 to 1 Sep 2013 as reported by ClinicalTrials.gov.
    • 28 Feb 2011 Actual end date (Jan 2011 ) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top